Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 115-122

  Ma, Guangyu ^a,b   Shimada, Hideaki ^a   Hiroshima, Kenzo ^b   Tada, Yuji ^b   Suzuki, Nobuo ^b   Tagawa, Masatoshi ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Adenovirus; Cancer; Clinical trials; E1B; Gene therapy; p53

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GENDICINE; NAVELBINE; ONCORINE; ONYX 015; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CHINA; CLINICAL STUDY; CLINICAL TRIAL; COLON CANCER; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL CARCINOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTHERMIC THERAPY; INFLUENZA; INJECTION SITE PAIN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; REVIEW; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 77951574435     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Ala-aho R, Grenman R, Seth P, et al. 2002. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene, 21:1187-1195 (Pubitemid 34185235)
2. Bischoff J, Kirn D, Williams A, et al. 1996. An adenovirus mutant that replicates selectively in p53 deficient human tumor cells. Science, 274:373-376 (Pubitemid 26353341)
3. Blagosklonny MV, EL-Deiry WS. 1996. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer, 67:386-392 (Pubitemid 26274130)
4. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. 1998. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab, 83:2516-2522 (Pubitemid 28503056)
5. Bouvard V, Zaitchouk T, Vacher M, et al. 2000. Tissue and cell-specific expression of the p53 target genes: bax, fas, mdm2 and waf1/p21, before and following ionizing irradiation in mice. Oncogene, 19:649-660
6. Cerrato JA, Yung WK, Liu TJ. 2001. Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. Neuro Oncol, 3:113-122
7. Cerwenka A, Lanier LL. 2003. NKG2D ligands: Unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens, 61:335-343 (Pubitemid 36605666)
8. Chen C, Pan J, Xu L. 2003. Recombinant adenovirus p53 agent injection combince with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II clinical trial. Zhonghua Yi Xue Za Zhi, 23:2033-2035
9. Chipuk JE, Kuwana T, Bouchier-H, et al. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 303:1010-1014
10. Chu RL, Post DE, Khuri FR, et al. 2004. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res, 10:5299-5312
11. Clayman GL, EL-Naggar AK, Lippman, et al. 1998. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol, 16:2221-2232 (Pubitemid 28265061)
12. Dameron KM, Volpert OV, Tainsky MA, et al. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265:1582-1584
13. Deweese TL, Vander PH, Li S, et al. 2001. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res, 61:7464-7472 (Pubitemid 32995035)
14. Eisold S, Linnebacher M, Ryschich E, et al. 2004. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol, 10:3583-3589 (Pubitemid 39619273)
15. Fulci G, Ishii N, Van Meir EG. 1998. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol, 8:599-613. (Pubitemid 28460920)
16. Guan YS, Sun L, Zhou XP, et al. 2005. Combination therapy with recombinant adenovirus-p53 injection (rAd-p53) via transcatheter hepatic arterial chemoembolization for advanced hepatic carcinoma. Shijie Huaren Xiaohua Zazhi, 13:125-127
17. Habib NA, Hodgson HJ, Lemoine N, et al. 1999. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumors. Hum Gene Ther, 10:2019-2034 (Pubitemid 29387916)
18. Huang XF, Ren W, Rollins L, et al. 2003. A broadly applicable personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res, 63:7321-7329 (Pubitemid 37420028)
19. Hu F, Hu X, Yu P, et al. 2006. Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating. Ai Zheng, 25:919-924
20. Inoue A, Narumi K, Matsubara N, et al. 2000. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anticancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett, 157:105-112 (Pubitemid 30421238)
21. Katayose D, Gudas J, Nguyen H, et al. 1995. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res, 1:889-897
22. Krishna R, Mayer LD. 2000. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11:265-283
23. Leu J, Dumont P, Hafey M, et al. 2004. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol, 6:443-450 (Pubitemid 38607505)
24. Lu Y, Hu X, Li F, et al. 2006. Radiotherapy combined with chemotherapy and intratumoral injection of EIB gene-deleted adenovirus (H101) for nasopharyngeal carcinoma. Zhong Liu, 26:453-455
25. Matsuda K, Yoshida K, Taya Y, et al. 2002. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res, 62:2883-2889 (Pubitemid 34525775)
26. Muller M, Wilder S, Bannasch D, et al. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med, 188:2033-2045 (Pubitemid 28562520)
27. Nemunaitis J, Swisher SG, Timmons T, et al. 2000. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol, 18:609-622 (Pubitemid 30078542)
28. Nemunaitis J, Cunningham C, Tong AW, et al. 2003. Pilot trial of intravenous infusion of a replication selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther, 10:341-352
29. O'Shea CC, Soria C, Bagus B, et al. 2005. Heat shock phenocopies E1B- 55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell, 8:61-74.
30. Pagliaro LC, Keyhani A, Williams D, et al. 2003. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J Clin Oncol, 21:2247-2253
31. Pal S, Datta K, Mukhopadhyay D. 2001. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res, 61:6952-6957 (Pubitemid 32896524)
32. Quist SR, Wang-Gohrke S, Kohler T, et al. 2004. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther, 11:547-554
33. Reid T, Galanis E, Abbruzzese J, et al. 2002. Hepatic arterial infusion of a replicationselective oncolytic adenovirus (dl520): Phase II viral, immunologic, and clinical endpoints. Cancer Res, 62:6070-6079
34. Rogulski KR, Freytag SO, Zhang K, et al. 2000. In vivo antitumor activity of ONYX-015 is influenced by radiotherapy. Cancer Res, 60:1193-1196
35. Rosenblum MD, Olasz E, Woodliff JE, et al. 2004. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood, 103:2691-2698
36. Rother K, Johne C, Spiesbach K, et al. 2004. Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene, 23:3376-3384
37. Rothmann T, Hengstermann A, Whitaker NJ, et al. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol, 72:9470-9478
38. Royds JA, Hibma M, Dix BR, et al. 2006. p53 promotes adenoviral replication and increases late viral gene expression. Oncogene, 25:1509-1520
39. Sabine L. 2004. Can China bring its own pipeline to the market? Nat Biotechnol, 22:1497-1499
40. Sah NK, Munshi A, Nishikawa T, et al. 2003. Adenovirus-mediated wild type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. Mol Cancer Ther, 2:1223-1231
41. Schuler M, Herrman R, DE Greve JL, et al. 2001. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol, 19:1750-1758
42. Schwartzenberg-bar-Yoseph F, Armoni M, Karnieli E, 2004. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res, 64:2627-2633
43. Shiraishi K, Kato S, Han SY, et al. 2004. Isolation of temperaturesensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem, 279:348-355
44. Singh B, Reddy PG, Goberdhan A, et al. 2002. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev, 16:984-993
45. Smith RR, Huebner RJ, Rowe WP, et al. 1956. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer, 9:1211-1218
46. St John LS, Sauter ER, Herlyn M, et al. 2000. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther, 7:749-756 (Pubitemid 30314059)
47. Sun Y, Zeng XR, Wenger L, et al. 2004. p53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem, 92:258-269
48. Swisher SG, Roth JA, Nemunaitis J, et al. 1999. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst, 91:763-771 (Pubitemid 29239055)
49. Taha TA, Osta W, Kozhaya L, et al. 2004. Down-regulation of sphingosine kinase-1 by DNA damage: Dependence on proteases and p53. J Biol Chem, 279:20546-20554 (Pubitemid 38623502)
50. Toschi E, Rota R, Antonini A, et al. 2000. Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells. J Invest Dermatol, 114:1188-1194 (Pubitemid 30415238)
51. Wang H, Qian H, Yu J, et al. 2006. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther, 5:380-385
52. Wang XY, Li Y, Yang G, et al. 2005. Current ideas about applications of heat shock proteins in vaccine design and immunotherapy. Int J Hyperthermia, 21:717-722 (Pubitemid 41807098)
53. Weng Z, Qin TL, Tan SY, et al. 2004. Clinical trial for the treatment of advanced lung cancer by intratumoral injection of rAd p53. Shenzhen Zhong Xi Yi Jie He Za Zhi, 14:206-210
54. White E. 1994. Tumour biology: p53, guardian of Rb. Nature, 371:21-22
55. Xia ZJ, Chang JH, Zhang L, et al. 2004. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng, 23:1666-1670
56. Xiao S, Liu C, Sun Y, et al. 2007. Clinical observation of the effect of recombinant adenovirus- p53 plus radio-thermotherapy on soft tissue sarcoma. Zhong Guo Zhong Liu Lin Chuang, 34:65-67
57. Yen N, Ioannides CG, Xu K, et al. 2000. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wildtype P53 (Ad-p53). Cancer Gene Ther, 7:530-536 (Pubitemid 30326888)
58. Yew PR, Berk AJ, 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature, 357:82-85
59. Yin Y, Liu YX, Jin YJ, et al. 2003. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature, 422:527-531 (Pubitemid 36433648)
60. Zeimet AG, Marth C. 2003. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol, 4:415-422 (Pubitemid 36833683)
61. Zhan J, Gao Y, Wang W, et al. 2005. Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Ther, 12:19-25. (Pubitemid 39665239)
62. Zhang S, Xiao S, Liu C, et al. 2003. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi, 23:2023-2028
63. Zhou C, Xu Y, Ni J, et al. 2006. Oncolytic adenovirus H101 in combination with vinorelbine/ cisplatin chemotherapy for advanced non-small cell lung cancer. Zhong Liu, 26:613-617